Ocrevus 300mg/10ml Injection
Ocrevus 300mg/10ml Injection (Ocrelizumab) is a prescription monoclonal antibody therapy used in the treatment of Multiple Sclerosis (MS), specifically relapsing forms of MS (RMS) and primary progressive MS (PPMS). It works by selectively targeting CD20-positive B cells, which play a key role in the inflammatory processes of MS.
Each vial contains 300mg of Ocrelizumab in 10ml solution, intended for intravenous (IV) infusion in a controlled medical setting. The infusion helps reduce the frequency of relapses, slow disability progression, and limit new lesion formation as seen on MRI scans.
Ocrevus is typically administered as two initial doses of 300mg spaced two weeks apart, followed by a 600mg maintenance dose every six months. Treatment should always be conducted under the supervision of a healthcare professional experienced in managing MS.
Before infusion, patients are often given premedications such as corticosteroids and antihistamines to minimize infusion-related reactions, which are the most common side effects.
Possible adverse effects include upper respiratory infections, infusion-related reactions (itching, rash, throat irritation), and in rare cases, increased risk of infections or malignancies. Regular monitoring of immune status is necessary throughout the treatment period.
Store Ocrevus vials in a refrigerator at 2°C to 8°C, protected from light, and do not freeze.
Ocrevus 300mg/10ml Injection (Ocrelizumab) is an FDA-approved humanized monoclonal antibody designed for the treatment of Multiple Sclerosis (MS), including both relapsing forms (RMS) and primary progressive MS (PPMS). Ocrelizumab functions by depleting CD20-positive B lymphocytes, which contribute to myelin sheath damage in the central nervous system.
Ocrevus is highly effective in reducing the annual relapse rate, slowing disability progression, and reducing the number of new or enlarging brain lesions in MS patients. It is considered a first-line therapy for patients with active MS due to its targeted mechanism and well-studied safety profile.
Each vial delivers 300mg of Ocrelizumab in 10ml of solution, which is diluted and administered via intravenous infusion. The standard dosing schedule involves:
An initial dose split into two 300mg infusions given two weeks apart.
A maintenance dose of 600mg administered every six months.
Infusions are conducted in specialized infusion centers where patients are monitored for potential adverse reactions during and after the procedure. Premedications, including corticosteroids and antihistamines, are commonly administered prior to infusion to reduce the risk of infusion-related reactions.
Common side effects include mild-to-moderate infusion reactions, respiratory tract infections, and skin infections. Rare but serious adverse effects may involve immunosuppression, resulting in an increased risk of infections or malignancies, which necessitates regular patient monitoring.
Ocrevus is contraindicated in patients with active infections and should be used cautiously in immunocompromised individuals. Vaccinations should be completed at least 6 weeks prior to initiating therapy.
Store unopened Ocrevus vials in a refrigerator at 2°C to 8°C. Protect from light and do not freeze.
For a comprehensive selection of immunotherapies and MS treatments, browse our Medicine Category. Visit our online pharmacy shop for more healthcare products.
Related products
